- Home
- OPHC vs GANX Comparison
OPHC vs GANX Comparison
Compare OPHC & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPHC | GANX |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | United States | United States |
| Employees | 98 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.5M | 78.2M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OPHC | GANX |
|---|---|---|
| Price | $5.46 | $1.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $6.50 | ★ $7.50 |
| AVG Volume (30 Days) | 21.4K | ★ 626.0K |
| Earning Date | 04-24-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ 0.20 | N/A |
| Revenue | N/A | ★ $55,180.00 |
| Revenue This Year | $17,095.98 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $27.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.91 | $1.41 |
| 52 Week High | $5.64 | $4.34 |
Technical Indicators
Market Signals| Indicator | OPHC | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 55.12 | 43.56 |
| Support Level | $5.40 | $1.65 |
| Resistance Level | $5.60 | $2.10 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 84.76 | 36.54 |
Price Performance
Historical ComparisonAbout OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. The services provided by the bank include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, borrowings, repayment of loans, money market deposit accounts, debit cards, automated teller machines, and other bank related services.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.